One Patient's story: blood thinners for severe hemophilia a

NCT ID NCT07314983

Recruiting now Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reports on a single adult with severe hemophilia A who is receiving long-term anticoagulation (blood thinners). The goal is to see if newer factor VIII therapies can maintain safe clotting levels while preventing dangerous clots. Only one participant is enrolled, so the findings are very preliminary and may not apply to others.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: factor VIII replacement therapy with prolonged half-life
What this could lead to: If successful, this could show that long-term anticoagulation is possible in severe hemophilia A, opening a new management option for these patients.
What could go wrong: This is a single-patient case report, not a controlled trial. Results may not apply to others, and the balance between bleeding and clotting risks remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A severe hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A

Contacts and locations

Locations

Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France
RECRUITING

Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.